Thymic Carcinoma Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Thymic carcinoma, also known as thymomas, is a rare type of cancer that forms in the cells present in the outside surface of the thymus. Thymus is a small organ that lies in the upper chest under the breastbone. It is a part of the lymph system and produces certain types of white blood cells that helps the body to fight against infections. The tumor cells in a thymoma look like the normal cells of the thymus which grow slowly and rarely spread beyond the thymus.

The drug candidates of thymic carcinoma disease pipeline include, but not limited to, pembrolizumab, and milciclib maleate. Some of the companies having drugs in the thymic carcinoma disease pipeline includes Merck & Co. Inc., NMS Group SpA and Tiziana Life Sciences plc.

• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.